Initial management strategies for follicular lymphoma.

Follicular lymphoma (FL) can vary markedly in its initial presentation, and no single standard approach for its initial management has been adopted. Available options for the initial management of FL include watchful waiting, radiation, single-agent rituximab and combination of rituximab and chemotherapy with strategies segregated for patients who have low and high tumor burden disease based on established criteria. However, marked debate occurs regarding the role of watchful waiting in the modern era for low tumor burden, asymptomatic patients, the optimal timing of rituximab, the selection of chemotherapy regimen to partner with rituximab in high tumor burden patients, and strategies for the management of relapsed disease. We provide an evidence-based discussion on these and other issues regarding the management of FL, and propose a mathematical modeling approach for addressing some of these questions.

[1]  J. Cerhan,et al.  Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Pileri,et al.  R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL). , 2012 .

[3]  J. Leonard,et al.  CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. , 2012 .

[4]  M. Czuczman,et al.  Ofatumumab demonstrates activity against rituximab‐sensitive and ‐resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B‐cell lymphoma , 2012, British journal of haematology.

[5]  J. Cerhan,et al.  A Comparison of the Effectiveness of First-Line Chemoimmunotherapy Regimens for Follicular Lymphoma (FL) Used in the United States , 2011 .

[6]  J. Cerhan,et al.  Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL) , 2011 .

[7]  R. Gascoyne,et al.  Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma , 2011 .

[8]  M. Taniwaki,et al.  Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Cerhan,et al.  Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National LymphoCare Study (NLCS): A U.S. patient cohort treated predominantly in community practices. , 2011, Journal of Clinical Oncology.

[10]  D. Berry,et al.  S20 Changing the guidelines for breast cancer screening: modeling mammography benefits and harms , 2011 .

[11]  Andrew Lister,et al.  Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial , 2011, The Lancet.

[12]  Joelle Pineau,et al.  Informing sequential clinical decision-making through reinforcement learning: an empirical study , 2010, Machine Learning.

[13]  J. Armitage,et al.  A decade of progress in lymphoma: advances and continuing challenges. , 2010, Clinical lymphoma, myeloma & leukemia.

[14]  K. Ardeshna,et al.  An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis , 2010 .

[15]  R. Ulrich,et al.  Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma , 2010 .

[16]  R. Advani,et al.  The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study , 2010 .

[17]  J. Vose,et al.  Improving Outcomes for Patients with Diffuse Large B‐cell Lymphoma , 2010, CA: a cancer journal for clinicians.

[18]  Oguzhan Alagöz,et al.  Optimal Breast Biopsy Decision-Making Based on Mammographic Features and Demographic Factors , 2010, Oper. Res..

[19]  C. Pascutto,et al.  Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients , 2010, British journal of haematology.

[20]  J. Byrd,et al.  NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[21]  C. Flowers.  Improving our use and understanding of antibodies in B-cell lymphomas. , 2010, Oncology.

[22]  J. Cerhan,et al.  Follicular lymphoma in the United States: first report of the national LymphoCare study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Rossi,et al.  Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. , 2008, Blood.

[24]  S. Horning,et al.  Follicular lymphoma: clinical features and treatment. , 2008, Hematology/oncology clinics of North America.

[25]  M. Baccarani,et al.  A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium‐90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non‐Hodgkin lymphoma , 2008, Cancer.

[26]  Ree Dawson,et al.  Adaptive treatment strategies in chronic disease. , 2008, Annual review of medicine.

[27]  Lijun Wang,et al.  Development of a simulation model of colorectal cancer , 2007, TOMC.

[28]  C. Flowers,et al.  Maintenance therapy in lymphoma. , 2007, Clinical lymphoma & myeloma.

[29]  Karen M Kuntz,et al.  Multiparameter calibration of a natural history model of cervical cancer. , 2007, American journal of epidemiology.

[30]  T. Ittel,et al.  Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Rivera,et al.  Using engineering control principles to inform the design of adaptive interventions: a conceptual introduction. , 2007, Drug and alcohol dependence.

[32]  Susan A Murphy,et al.  Customizing treatment to the patient: adaptive treatment strategies. , 2007, Drug and alcohol dependence.

[33]  Joelle Pineau,et al.  Constructing evidence-based treatment strategies using methods from computer science. , 2007, Drug and alcohol dependence.

[34]  G. Salles,et al.  Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years. , 2006 .

[35]  W. Hiddemann,et al.  Recommendations for the use of Yttrium‐90 ibritumomab tiuxetan in malignant lymphoma , 2006, Cancer.

[36]  P. Solal-Céligny,et al.  Follicular lymphoma international prognostic index , 2006, Blood.

[37]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[38]  R. Marcus,et al.  Follicular lymphoma: time for a re-think? , 2005, Blood reviews.

[39]  T. Habermann,et al.  Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  R. Marcus,et al.  CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.

[41]  J. Armitage,et al.  Follicular lymphoma: expanding therapeutic options. , 2005, Oncology.

[42]  Andrew J. Schaefer,et al.  The Optimal Timing of Living-Donor Liver Transplantation , 2004, Manag. Sci..

[43]  Susan A. Murphy,et al.  A Conceptual Framework for Adaptive Preventive Interventions , 2004, Prevention Science.

[44]  M. Ghielmini,et al.  Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. , 2004, Blood.

[45]  K. Maclennan,et al.  Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial , 2003, The Lancet.

[46]  S. Murphy,et al.  Optimal dynamic treatment regimes , 2003 .

[47]  S. Tucker,et al.  Long-term results with radiotherapy for Stage I-II follicular lymphomas. , 2001, International journal of radiation oncology, biology, physics.

[48]  Ree Dawson,et al.  Flexible treatment strategies in chronic disease: clinical and research implications , 2000, Biological Psychiatry.

[49]  Milos Hauskrecht,et al.  Planning treatment of ischemic heart disease with partially observable Markov decision processes , 2000, Artif. Intell. Medicine.

[50]  H. Tilly,et al.  Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  K. Maclennan,et al.  Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. , 1994, British Journal of Cancer.

[52]  E. Jaffe,et al.  The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. , 1988, Seminars in hematology.

[53]  S. Horning,et al.  The natural history of initially untreated low-grade non-Hodgkin's lymphomas. , 1984, The New England journal of medicine.

[54]  G. Salles,et al.  Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study , 2011 .

[55]  M. Ghielmini,et al.  Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  M. Gordon,et al.  Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma , 2009 .

[57]  Andrew J. Schaefer,et al.  The Optimal Time to Initiate HIV Therapy Under Ordered Health States , 2008, Oper. Res..

[58]  Andrew J. Schaefer,et al.  Determining the Acceptance of Cadaveric Livers Using an Implicit Model of the Waiting List , 2007, Oper. Res..

[59]  A. Zanella,et al.  Anti-erythroblast autoimmunity in early myelodysplastic syndromes. , 2007, Haematologica.

[60]  M. Czuczman.  Controversies in follicular lymphoma: "who, what, when, where, and why?" (not necessarily in that order!). , 2006, Hematology. American Society of Hematology. Education Program.

[61]  Milton C Weinstein,et al.  Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[62]  P. Henry.  Not Necessarily In That Order , 1996 .

[63]  S. Rosenberg,et al.  No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. , 1979, Annals of internal medicine.